INDIGO: Switching B Cells Off, Not Out, in IgG4-Related Disease Save

IgG4-related disease is a fibroinflammatory (IgG4-RD) condition that can involve almost any organ, and it punishes delay: close to 60% of patients already carry irreversible damage at diagnosis. Glucocorticoids induce remission in most, but a third to two-thirds relapse once they stop, and the cumulative toxicity lands on an older, comorbid population. B-cell targeting has moved to the centre of treatment, with inebilizumab, a CD19 depleter, as the recent benchmark. At EULAR 2026, INDIGO tested whether the disease can be controlled by switching B cells off rather than depleting them.

Della-Torre and colleagues presented the phase 3 INDIGO trial (OP018), also published this week in the New England Journal of Medicine. Obexelimab is a bifunctional antibody that coengages CD19 and the inhibitory receptor FcγRIIb, suppressing B-cell activation without clearing the lineage. 194 patients were randomized one to one to weekly subcutaneous obexelimab or placebo for 52 weeks, after a standardized steroid taper to discontinuation by week 8.

The trial hit its primary endpoint cleanly. Obexelimab reduced the risk of flare requiring rescue by 56% (HR 0.44, 95% CI 0.28 to 0.71, p=0.0005); 73% of treated patients stayed flare-free through the year, against a flare rate of 54.6% on placebo. All four key secondary endpoints followed, including complete remission (37.1% vs 19.6%) and a sharp drop in cumulative rescue glucocorticoid (329.5 mg vs 929.8 mg). The glucocorticoid toxicity index moved the same way. Safety was reassuring, with no new signals, fewer serious adverse events than placebo (10.3% vs 18.6%), and no increase in infection, the theoretical payoff of leaving the B-cell compartment intact.

The clinic question is narrower. Obexelimab is maintenance, not cure: it prevents flares and spares steroids, and, as with nearly all of our options, it does not reverse fibrosis that is already established. Its potential advantage is mechanistic. Suppressing B cells without lymphodepleting them may preserve more of normal humoral immunity, and that gentler footprint, more than the flare numbers, may be what ultimately distinguishes it. The honest caveats are about maturity rather than mechanism: one year of follow-up, durability and long-term safety still unproven, and an unsettled place in the treatment sequence.

What it does add is real: a large effect on flares and meaningful steroid-sparing in the population that tolerates steroids worst, delivered by a B-cell strategy that leaves the compartment intact. For a disease we mostly manage by chasing relapses and limiting glucocorticoids, that combination is a useful addition. Whether obexelimab earns a front-line role will depend on longer data, and on whether the non-depleting approach translates into the durable safety advantage its mechanism promises.